Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Viral Infections

Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir

Abstract

We examined the incidence of herpes varicella-zoster virus (VZV) infection in 151 patients undergoing allogeneic BMT between August 1990 and September 1997 and who survived at least 3 months. Median follow-up was 17 (range 3.3–80.7) months. Herpes simplex virus antibody positive (HSV+) patients received aciclovir 1200 mg p.o. daily or 750 mg i.v. daily, in divided doses from day 0 to engraftment. Ganciclovir (5 mg/kg i.v. three times per week) was given in CMV+ patients (or if the donor was CMV+) from engraftment to day 84. Ganciclovir was continued or recommenced if a dose of greater than 20 mg of prednisone was used for the treatment of GVHD otherwise aciclovir was recommenced. In HSV+ patients not receiving ganciclovir, aciclovir 600 mg p.o. daily in divided doses was given until at least 6 months after BMT. Thirty-two patients developed VZV infection from 4.1 to 28 months after transplant. The estimated cumulative incidence of VZV was 13% (95% confidence interval 6–19%) at 12 months, 32% (22–42%) at 24 months and 38% (27–50%) at 28 months, with no further cases beyond that time. No patient developed VZV whilst receiving aciclovir or ganciclovir (P < 0.0001). However, there was a rapid onset of VZV following cessation of antiviral therapy (33% (20–46%) at 1 year post cessation). The presence of GVHD and the prior duration of antiviral prophylaxis were significant and independent risk factors for the development of VZV. Age, underlying disease, conditioning therapy or donor type were not. we conclude that 3–6 months of low-dose aciclovir and ganciclovir are effective at delaying the onset of VZV after allogeneic BMT, but may not affect the overall incidence of infection. Prolonged prophylaxis may be warranted in patients at high risk of infection, for example those patients with GVHD. Bone Marrow Transplantation (2000) 25, 657–664.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Han CS, Miller W, Haake R, Weisdorf D . Varicella zoster virus after bone marrow transplantation: incidence, risk factors and complications Bone Marrow Transplant 1994 13: 277–283

    CAS  PubMed  Google Scholar 

  2. Locksley RM, Flournoy N, Sullivan KM, Meyers JD . Infection with varicella-zoster virus after marrow transplantation J Infect Dis 1985 152: 1172–1181

    Article  CAS  Google Scholar 

  3. Atkinson K, Meyers JD, Storb R et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia Transplantation 1980 29: 47–50

    Article  CAS  Google Scholar 

  4. Tzeng CH, Liu JH, Fan S et al. Varicella zoster virus infection after allogeneic or autologous hemopoietic stem cell transplantation J Formos Med Assoc 1995 94: 313–317

    CAS  PubMed  Google Scholar 

  5. Koc Y, Miller K, Schenkein D et al. Varicella zoster virus (VZV) infections following allogeneic bone marrow transplantation (BMT): frequency, risk factors, clinical outcome and antiviral prophylaxis Blood 1997 90: (Suppl. 1) 543a

    Google Scholar 

  6. Schuchter LM, Wingard JR, Piantadosi S et al. Herpes zoster infection after autologous bone marrow transplantation Blood 1989 74: 1424–1427

    CAS  PubMed  Google Scholar 

  7. Saral R, Burns WH, Laskin OL et al. Acyclovir prophylaxis of herpes-simplex virus infections New Engl J Med 1981 305: 63–67

    Article  CAS  Google Scholar 

  8. Gluckman E, Lotsberg J, Devergie A et al. Prophylaxis of herpes infections after bone marrow transplantation by oral acyclovir Lancet 1983 2: 706–708

    Article  CAS  Google Scholar 

  9. Selby PJ, Powles RL, Easton D et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation Br J Cancer 1989 59: 434–438

    Article  CAS  Google Scholar 

  10. Ljungman P, Lonnqvist B, Gahrton G et al. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients J Infect Dis 1986 153: 840–847

    Article  CAS  Google Scholar 

  11. Whitley R, Gnann J . Acyclovir: a decade later New Engl J Med 1992 327: 782–789

    Article  CAS  Google Scholar 

  12. Abraham R, Szer J, Bardy P, Grigg A . Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants Bone Marrow Transplant 1997 20: 773–777

    Article  CAS  Google Scholar 

  13. Atkinson K, Arthur C, Bradstock K et al. Prophylactic ganciclovir is more effective in HLA-identical family member recipients than in more heavily immune-suppressed HLA-identical unrelated marrow transplant recipients Bone Marrow Transplant 1995 16: 401–406

    CAS  PubMed  Google Scholar 

  14. Koc Y, Miller K, Schenkein D et al. Ganciclovir administration for cytomegalovirus infection prophylaxis delays onset of varicella zoster virus reactivation in allogeneic bone marrow transplant recipients Blood 1997 92: (Suppl. 1) 280a

    Google Scholar 

  15. Wilson A, Sharp M, Koropchak CM et al. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation J Infect Dis 1992 165: 119–126

    Article  CAS  Google Scholar 

  16. Saxon A, McIntyre RE, Stevens RH, Gale RP . Lymphocyte dysfunction in chronic graft-versus-host disease Blood 1981 58: 746–751

    CAS  PubMed  Google Scholar 

  17. Witherspoon RP, Lum LG, Storb R . Immunologic reconstitution after human marrow grafting Semin Hematol 1984 21: 2–10

    CAS  PubMed  Google Scholar 

  18. Santos GW, Hess AD, Vogelsang GB . Graft-versus-host reactions and disease Immunol Rev 1985 88: 169–192

    Article  CAS  Google Scholar 

  19. Meyers JD, Flournoy N, Thomas ED . Cell-mediated immunity to varicella-zoster virus after allogeneic marrow transplant J Infect Dis 1980 141: 479–487

    Article  CAS  Google Scholar 

  20. Lekstrom-Himes J, Straus S . Varicella zoster virus infections in the normal and immunocompromised host. In: Sacks SL, Straus SE, Whitley RJ, Griffiths PD (eds) Clinical Management of Herpes Viruses IOS Press: Amsterdam 1995 pp 175–192

    Google Scholar 

  21. Ellis MN, Martin JL, Lobe DC . Induction of acyclovir-resistant mutants of herpes simplex virus type 1 in athymic nude mice J Antimicrob Chemother 1986 18: (Suppl. B) 95–101

    Article  CAS  Google Scholar 

  22. Matthews T, Boehme R . Antiviral activity and mechanism of action of ganciclovir Rev Infect Dis 1988 10: (Suppl. 3) S490–S494

    Article  CAS  Google Scholar 

  23. Soike KF, Eppstein DA, Gloff CA . Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and recombinant human beta interferon alone and in combination on simian varicella virus infection in monkeys J Infect Dis 1987 156: 607–614

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Partial funding for the analysis was provided by Glaxo Wellcome Australia.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steer, C., Szer, J., Sasadeusz, J. et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 25, 657–664 (2000). https://doi.org/10.1038/sj.bmt.1702190

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702190

Keywords

This article is cited by

Search

Quick links